Hubungan Karakteristik Pasien Skizofrenia dengan Efek Samping Neurolectic Malignant Syndrome (NMS)

The Relationship Between the Characteristics of Schizophrenia Patients with Neuroleptic Malignant Syndrome (NMS)

Authors

  • Okta Puspita Universitas Gadjah Mada
  • Zullies Ikawati Universitas Gadjah Mada
  • Bambang Hastha Yoga Universitas Gadjah Mada
  • Ishak Ishak RSJ Prof. dr. Soerojo Magelang
  • Bindaria Mutmaina RSJ Dr. Radjiman Wediodiningrat Lawang

DOI:

https://doi.org/10.33084/jsm.v11i2.9760

Keywords:

Skizofrenia, Antipsikotik, Mortalitas, Neuroleptic malignant, Syndrome (NMS)

Abstract

Terapi antipsikotik yang menjadi salah satu penyebab terjadinya neuroleptic malignant syndrome (NMS) merupakan terapi utama pasien skizofrenia dan digunakan dalam terapi jangka panjang. Peningkatan kasus skizofrenia yang berhubungan dengan peningkatan penggunaan antipsikotik dan karakteristik yang berbeda pada tiap individu berisiko meningkatkan efek samping NMS hingga mortalitas. Penelitian ini bertujuan melihat hubungan antara karakteristik pasien skizofrenia dengan efek samping neuroleptic malignant syndrome (NMS). Penelitian dilakukan di RSJ Prof. dr. Soerojo Magelang dan RSJ Dr. Radjiman Wediodiningrat Lawang dengan rancangan observasional analitik case control secara retrospektif melalui data rekam medis pasien rawat inap periode Januari 2018 - Agustus 2023. Populasi penelitian terdiri dari 31 subyek untuk kelompok kasus (pasien skizofrenia yang mengalami NMS) dan 62 subyek untuk kelompok kontrol (pasien skizofrenia tidak mengalami NMS). Hasil analisis bivariat secara chi square dan fisher test tidak menunjukkan nilai yang signifikan antara hubungan karakteristik pasien (umur, jenis kelamin, obat lain, penyakit penyerta, jumlah antipsikotik dan dosis antipsikotik) skizofrenia dengan efek samping neuroleptic malignant syndrome (NMS). Penelitian ini menyimpulkan tidak terdapat hubungan antara karakteristik pasien skizofrenia dengan efek samping neuroleptic malignant syndrome (NMS).

Downloads

Author Biographies

Okta Puspita, Universitas Gadjah Mada

Zullies Ikawati, Universitas Gadjah Mada

Bambang Hastha Yoga, Universitas Gadjah Mada

Ishak Ishak, RSJ Prof. dr. Soerojo Magelang

Bindaria Mutmaina, RSJ Dr. Radjiman Wediodiningrat Lawang

References

Amato, D., Canneva, F., Cumming, P., Maschauer, S., Groos, D., Dahlmanns, J. K., Grömer, T. W., Chiofalo, L., Dahlmanns, M., Zheng, F., Kornhuber, J., Prante, O., Alzheimer, C., Von Hörsten, S., & Müller, C. P. (2020). A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: The role of the dopamine transporter. Molecular Psychiatry, 25(9), 2101–2118. https://doi.org/10.1038/s41380-018-0114-5

Barrera, A., Curwell-Parry, O., & Raphael, M.-C. (2019). Hebephrenia is dead, long live hebephrenia, or why Hecker and Chaslin were on to something. BJPsych Advances, 25(6), 373–376. https://doi.org/10.1192/bja.2019.24

Belvederi Murri, M., Guaglianone, A., Bugliani, M., Calcagno, P., Respino, M., Serafini, G., Innamorati, M., Pompili, M., & Amore, M. (2015). Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis. Drugs in R&D, 15(1), 45–62. https://doi.org/10.1007/s40268-014-0078-0

Berman, B. D. (2011). Neuroleptic Malignant Syndrome: A Review for Neurohospitalists. The Neurohospitalist, 1(1), 41–47. https://doi.org/10.1177/1941875210386491

Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015). A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. International Journal of Endocrinology, 2015, 1–16. https://doi.org/10.1155/2015/615356

Guinart, D., Taipale, H., Rubio, J. M., Tanskanen, A., Correll, C. U., Tiihonen, J., & Kane, J. M. (2021). Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin, 47(6), 1621–1630. https://doi.org/10.1093/schbul/sbab062

Gurrera, R. J. (2017). A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatrica Scandinavica, 135(5), 398–408. https://doi.org/10.1111/acps.12694

Hirofuji, S., Miyasaka, K., Maezawa, M., Wakabayashi, W., Oura, K., Nakao, S., Ichihara, N., Nokura, Y., Yamashita, M., Matsui, K., Tanaka, H., Masuta, M., Ieiri, I., Iguchi, K., & Nakamura, M. (2023). Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system. Heliyon, 9(11), e21891. https://doi.org/10.1016/j.heliyon.2023.e21891

Kementerian Kesehatan Republik Indonesia. [2018]. InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI: Situasi Kesehatan Jiwa di Indonesia,Jakarta, Kementerian Kesehatan Republik Indonesia

Kim, H.-Y., Lee, H.-W., Jung, S.-H., Kang, M.-H., Bae, J.-N., Lee, J.-S., & Kim, C.-E. (2014). Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy. Clinical Psychopharmacology and Neuroscience, 12(2), 128–136. https://doi.org/10.9758/cpn.2014.12.2.128

Kimura, G., Kadoyama, K., Brown, J. B., Nakamura, T., Miki, I., Nisiguchi, K., Sakaeda, T., & Okuno, Y. (2015). Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database. International Journal of Medical Sciences, 12(2), 135–140. https://doi.org/10.7150/ijms.10453

Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: A review. British Medical Bulletin, 114(1), 169–179. https://doi.org/10.1093/bmb/ldv017

Nielsen, R. E., Jensen, S. O. W., & Nielsen, J. (2012). Neuroleptic Malignant Syndrome—An 11-Year Longitudinal Case-Control Study. The Canadian Journal of Psychiatry, 57(8), 512–518. https://doi.org/10.1177/070674371205700810

Nishanth, K. N., Chadda, R. K., Sood, M., Biswas, A., & Lakshmy, R. (2017). Physical comorbidity in schizophrenia & its correlates. INDIAN J MED RES.

Oneib, B., & Zaimi, O. (2021). Neuroleptic malignant syndrome: Clinical expression, complication, course, and atypical clinical picture. Middle East Current Psychiatry, 28(1), 1. https://doi.org/10.1186/s43045-020-00081-6

Oruch, R., Pryme, I., Engelsen, B., & Lund, A. (2017). Neuroleptic malignant syndrome: An easily overlooked neurologic emergency. Neuropsychiatric Disease and Treatment, Volume 13, 161–175. https://doi.org/10.2147/NDT.S118438

Pankiewicz-Dulacz, M., Stenager, E., Chen, M., & Stenager, E. (2018). Incidence Rates and Risk of Hospital Registered Infections among Schizophrenia Patients before and after Onset of Illness: A Population-Based Nationwide Register Study. Journal of Clinical Medicine, 7(12), 485. https://doi.org/10.3390/jcm7120485

Paton, C., Barnes, T. R. E., Cavanagh, M.-R., Taylor, D., & Lelliott, P. (2008). High-dose and combination antipsychotic prescribing in acute adult wards in the UK: The challenges posed by p.r.n. prescribing. British Journal of Psychiatry, 192(6), 435–439. https://doi.org/10.1192/bjp.bp.107.042895

Sarkar, S., & Gupta, N. (2017). Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association. BJPsych Bulletin, 41(4), 211–216. https://doi.org/10.1192/pb.bp.116.053736

Severance, E. G., Prandovszky, E., Castiglione, J., & Yolken, R. H. (2015). Gastroenterology Issues in Schizophrenia: Why the Gut Matters. Current Psychiatry Reports, 17(5), 27. https://doi.org/10.1007/s11920-015-0574-0

Shaikh, N., Al-Sulaiti, G., Nasser, A., & Rahman, M. (2011). Neuroleptic malignant syndrome and closed head injury: A case report and review. Asian Journal of Neurosurgery, 6(02), 101–105. https://doi.org/10.4103/1793-5482.92173

Stevens, D. L. (2008). Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome. Annals of Pharmacotherapy, 42(9), 1290–1297. https://doi.org/10.1345/aph.1L066

Strawn, J. R., Keck, P. E., & Caroff, S. N. (2007). Neuroleptic Malignant Syndrome. Am J Psychiatry.

Su, Y.-P., Chang, C.-K., Hayes, R. D., Harrison, S., Lee, W., Broadbent, M., Taylor, D., & Stewart, R. (2014). Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 130(1), 52–60. https://doi.org/10.1111/acps.12222

Tse, L., Barr, A., Scarapicchia, V., & Vila-Rodriguez, F. (2015). Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Current Neuropharmacology, 13(3), 395–406. https://doi.org/10.2174/1570159X13999150424113345

Tural, Ü., & Önder, E. (2010). Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry and Clinical Neurosciences, 64(1), 79–87. https://doi.org/10.1111/j.1440-1819.2009.02042.x

Verma, R., Junewar, V., & Rathaur, B. P. S. (2014). An atypical case of neuroleptic malignant syndrome precipitated by valproate. Case Reports, 2014(mar06 1), bcr2013202578–bcr2013202578. https://doi.org/10.1136/bcr-2013-202578

Wadoo, O., Ouanes, S., & Firdosi, M. (2021). Neuroleptic malignant syndrome: A guide for psychiatrists. BJPsych Advances, 27(6), 373–382. https://doi.org/10.1192/bja.2020.71

Downloads

Published

2025-04-25

How to Cite

Puspita, O. ., Ikawati, Z., Yoga, B. H., Ishak, I., & Mutmaina, B. (2025). Hubungan Karakteristik Pasien Skizofrenia dengan Efek Samping Neurolectic Malignant Syndrome (NMS): The Relationship Between the Characteristics of Schizophrenia Patients with Neuroleptic Malignant Syndrome (NMS). Jurnal Surya Medika (JSM), 11(1), 288–296. https://doi.org/10.33084/jsm.v11i2.9760